FDA requires black-box warning on post-chemo anemia drugs

Makers of drugs used to treat patients with anemia that results from kidney failure or chemotherapy must add a black-box warning due to recent studies suggesting possible heart problems or death, the FDA says. The agency issued the new requirement for Amgen's Aranesp and Epogen and Johnson & Johnson's Procrit, which are genetically engineered forms of erythropoietin.

View Full Article in:

NYTimes.com · Washington Post (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR